Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.60 |
| ▸ | DRD4 | P21917 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7353904 | 0.93 | MCHR1 (0.55) | SLC6A5DRD4HTR2ADRD2MEN1 | |
| SCHEMBL7347684 | 0.87 | MCHR1 (0.53) | SLC6A5DRD4HTR2ADRD2MEN1 | |
| SCHEMBL6457611 | 0.87 | SLC6A5 (0.51) | SLC6A5DRD4HTR2ADRD2 | |
| SCHEMBL7350951 | 0.85 | DRD4 (0.47) | SLC6A5DRD4MEN1KMT2ASIGMAR1 | |
| SCHEMBL7345537 | 0.85 | SLC6A5 (0.44) | SLC6A5DRD4HTR2ADRD2 | |
| SCHEMBL7347675 | 0.84 | UTS2R (0.49) | DRD4MEN1KMT2A | |
| SCHEMBL7347703 | 0.83 | MCHR1 (0.49) | DRD4HTR2ADRD2SIGMAR1 | |
| SCHEMBL7347047 | 0.82 | MCHR1 (0.47) | DRD4HTR2ASIGMAR1 | |
| SCHEMBL7346827 | 0.80 | SSTR5 (0.47) | DRD4MEN1KMT2A | |
| SCHEMBL6466592 | 0.80 | HTR7 (0.55) | SLC6A5HTR2ADRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307051-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTAGONISTS AND HAVE ANTITUMOR AND ANTIMETASTATIC ACTIVITY. | ROCHE DIAGNOSTICS GMBH (DE) | 2001-10-23 | — | — | US | claimed |
| US-6307051-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTAGONISTS AND HAVE ANTITUMOR AND ANTIMETASTATIC ACTIVITY. | ROCHE DIAGNOSTICS GMBH (DE) | 2001-10-23 | — | — | US | disclosed |
| EP-1026165-A1 | O-substituted Hydroxycoumaranone derivatives as antitumor and antimetastatic agents | Roche Diagnostics GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |